검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lenvatinib Oral Product (Lenvatinib Oral Product) Merck Sharp & Dohme LLC·Merkel Cell Carcinoma ORR 64.8% |
|---|---|
Overview Program | Lenvatinib Oral Product |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Merkel Cell Carcinoma |
Overview Indication | Biliary Tract Neoplasms; Immunotherapy |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting of angiogenic and immune pathway |
MoA Biomarker | PD-L1 staining) showed a trend of high |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Pharmacokinetics and anti-tumor efficacy of transarterial chemoembolization using small-particle lenvatinib-loaded beads in a rabbit VX2 liver tumor model.. Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC); however, post-embolization hypoxia may induce vascular endothelial growth factor (VEGF)-mediated angiogenesis, thereby promot… |
Clinical Primary efficacy | ORR 64.8% |
Clinical ORR | 64.8% |
Clinical Result source | ClinicalTrials.gov NCT01321554 |
Clinical Data Tier / Score | A · 53 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lenvatinib Oral Product (Lenvatinib Oral Product) Merck Sharp & Dohme LLC·Merkel Cell Carcinoma ORR 64.8% |
|---|---|
Overview Program | Lenvatinib Oral Product |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Merkel Cell Carcinoma |
Overview Indication | Biliary Tract Neoplasms; Immunotherapy |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting of angiogenic and immune pathway |
MoA Biomarker | PD-L1 staining) showed a trend of high |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Pharmacokinetics and anti-tumor efficacy of transarterial chemoembolization using small-particle lenvatinib-loaded beads in a rabbit VX2 liver tumor model.. Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC); however, post-embolization hypoxia may induce vascular endothelial growth factor (VEGF)-mediated angiogenesis, thereby promot… |
Clinical Primary efficacy | ORR 64.8% |
Clinical ORR | 64.8% |
Clinical Result source | ClinicalTrials.gov NCT01321554 |
Clinical Data Tier / Score | A · 53 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교